It's no secret that Moderna's R&D efforts have expanded well beyond the realm of COVID-19. CFO Jamey Mock tells us that today the company has more than 40 drugs in its pipeline, with targets such …
Continue Reading about 963: How a Biotech Disrupter Is De-risking R&D | Jamey Mock, CFO, Moderna →